OssDsign AB (publ) publishes Year-end Report 2021

Another sales record marks the end of a transformative year for OssDsign.

The fourth quarter in figures

• Net sales amounted to TSEK 9,174 (6,760).
• Loss after taxes amounted to TSEK 28,726 (24,952).
• Earnings per share was SEK -0.5 (-1.1).
• Cash flow from current operations was TSEK -20,456 (-24,266).

The full year in figures

• Net sales amounted to TSEK 31,726 (24,872).
• Loss after taxes amounted to TSEK 94,077 (84,590).
• Earnings per share was SEK -1.9 (-4.4).
• Cash flow from current operations was TSEK -89,629 (-79,331).

Important events during the fourth quarter

• OssDsign receives expanded FDA market clearance for OssDsign Cranial PSI.
• First patients treated with OssDsign Catalyst in the U.S.
• Post-market surveillance shows continued low complication rates with OssDsign Cranial PSI.
• OssDsign receives Innovative Technology contract from Vizient for OssDsign Cranial PSI.
   

Important events after the end of the fourth quarter

• OssDsign receives Institutional Review Board approval to establish a clinical registry in the U.S. to collect real-world data on OssDsign Catalyst.
• OssDsign steps up ambition to generate further clinical evidence for its bone replacement products through key recruitment.

The Year-end 2021 results will also be presented at an investor webcast today February 22 at 11:30 CET. The webcast can be accessed via the following link https://www.finwire.tv/webcast/ossdsign/q4-presentation-2021/  or via the OssDsign website.  

For further information, please contact:

Morten Henneveld, CEO, OssDsign AB

Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser:

Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign

OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.

This information is information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08:00 CET on February 22, 2022.

Tags: